S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
NASDAQ:CAPR

Capricor Therapeutics (CAPR) Stock Forecast, Price & News

$4.55
0.00 (0.00%)
(As of 06/2/2023 ET)
Compare
Today's Range
$4.46
$4.64
50-Day Range
$3.76
$4.74
52-Week Range
$3.30
$6.58
Volume
60,252 shs
Average Volume
56,394 shs
Market Capitalization
$114.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

Capricor Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
262.6% Upside
$16.50 Price Target
Short Interest
Bearish
1.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$12,180 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.41) to $0.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

757th out of 983 stocks

Pharmaceutical Preparations Industry

380th out of 486 stocks


CAPR stock logo

About Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Receive CAPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CAPR Stock News Headlines

“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Cell Therapy Market Size, Share and Forecast 2031
Maxim Group Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)
See More Headlines

CAPR Price History

CAPR Company Calendar

Last Earnings
3/15/2023
Today
6/03/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CAPR
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+262.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-29,020,000.00
Pretax Margin
-523.02%

Debt

Sales & Book Value

Annual Sales
$2.55 million
Book Value
$0.25 per share

Miscellaneous

Free Float
22,111,000
Market Cap
$114.98 million
Optionable
Not Optionable
Beta
4.00

Key Executives

  • Frank I. Litvack M.D. (Age 59)
    Independent Executive Chairman of the Board
  • Linda Marban Ph.D. (Age 51)
    President, Chief Executive Officer, Director
  • Anthony Bergmann (Age 32)
    Chief Financial Officer, Principal Accounting Officer
  • Karen G. Krasney J.D. (Age 62)
    Executive Vice President, General Counsel
  • Thomas Lyle Copmann Ph.D. (Age 61)
    Vice President - Regulatory Affairs and Drug Development
  • Houman Hemmati M.D.
    Ph.D., Vice President - Medical & Clinical Development, New Therapies
  • Luis Rodriguez-Borlado Ph.D.
    Vice President - Regenerative Therapies
  • Rachel Smith Ph.D. (Age 36)
    Vice President - Research & Development
  • Deborah Ascheim M.D.
    Chief Medical Officer
  • Joshua A. Kazam (Age 40)
    Director













CAPR Stock - Frequently Asked Questions

Should I buy or sell Capricor Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CAPR shares.
View CAPR analyst ratings
or view top-rated stocks.

What is Capricor Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued 12 month price targets for Capricor Therapeutics' stock. Their CAPR share price forecasts range from $15.00 to $18.00. On average, they anticipate the company's stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 262.6% from the stock's current price.
View analysts price targets for CAPR
or view top-rated stocks among Wall Street analysts.

How have CAPR shares performed in 2023?

Capricor Therapeutics' stock was trading at $3.86 at the beginning of the year. Since then, CAPR shares have increased by 17.9% and is now trading at $4.55.
View the best growth stocks for 2023 here
.

Are investors shorting Capricor Therapeutics?

Capricor Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 294,800 shares, an increase of 11.0% from the April 30th total of 265,700 shares. Based on an average daily trading volume, of 72,100 shares, the days-to-cover ratio is presently 4.1 days.
View Capricor Therapeutics' Short Interest
.

When is Capricor Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our CAPR earnings forecast
.

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) released its quarterly earnings data on Wednesday, March, 15th. The biotechnology company reported ($0.31) EPS for the quarter. The biotechnology company had revenue of $0.96 million for the quarter, compared to analysts' expectations of $0.01 million.

What other stocks do shareholders of Capricor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD).

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

Who are Capricor Therapeutics' major shareholders?

Capricor Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.56%), Geode Capital Management LLC (0.92%), Dimensional Fund Advisors LP (0.39%), Renaissance Technologies LLC (0.12%), Commonwealth Equity Services LLC (0.12%) and Virtu Financial LLC (0.07%). Insiders that own company stock include David B Musket and Xavier Avat.
View institutional ownership trends
.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Capricor Therapeutics' stock price today?

One share of CAPR stock can currently be purchased for approximately $4.55.

How much money does Capricor Therapeutics make?

Capricor Therapeutics (NASDAQ:CAPR) has a market capitalization of $114.98 million and generates $2.55 million in revenue each year. The biotechnology company earns $-29,020,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The official website for the company is www.capricor.com. The biotechnology company can be reached via phone at 310-358-3200, via email at kimberly@argotpartners.com, or via fax at 415-875-7075.

This page (NASDAQ:CAPR) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -